COGS

Collaborative Oncological Gene-environment Study

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Agneta
Cognome: Haeggstroem
Email: send email
Telefono: +46 8 52486089
Fax: +46 8 314975

 Nazionalità Coordinatore Sweden [SE]
 Sito del progetto http://www.cogseu.org/
 Totale costo 16˙703˙903 €
 EC contributo 11˙715˙501 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-IP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-05-01   -   2014-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Agneta
Cognome: Haeggstroem
Email: send email
Telefono: +46 8 52486089
Fax: +46 8 314975

SE (STOCKHOLM) coordinator 1˙301˙573.10
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

 Organization address address: The Old Schools, Trinity Lane
city: CAMBRIDGE
postcode: CB2 1TN

contact info
Titolo: Mr.
Nome: Keith
Cognome: Cann
Email: send email
Telefono: +44 1223 333543
Fax: +44 1223 332988

UK (CAMBRIDGE) participant 3˙796˙030.50
3    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

 Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Mr.
Nome: Juan José
Cognome: Collazo Nieto
Email: send email
Telefono: 34917328000
Fax: 34912246980

ES (MADRID) participant 2˙300˙650.80
4    STICHTING HET NEDERLANDS KANKER INSTITUUT

 Organization address address: PLESMANLAAN 121
city: AMSTERDAM
postcode: 1066 CX

contact info
Titolo: Dr.
Nome: Henri
Cognome: Van Luenen
Email: send email
Telefono: +31 20 5122097
Fax: +31 20 6991383

NL (AMSTERDAM) participant 1˙087˙739.60
5    INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL

 Organization address address: Old Brompton Road 123
city: LONDON
postcode: SW7 3RP

contact info
Titolo: Ms.
Nome: Donna
Cognome: Conway
Email: send email
Telefono: +44 207 1535414
Fax: +44 207 1535534

UK (LONDON) participant 600˙674.80
6    DEUTSCHES KREBSFORSCHUNGSZENTRUM

 Organization address address: Im Neuenheimer Feld 280
city: HEIDELBERG
postcode: 69120

contact info
Titolo: Ms.
Nome: Bettina
Cognome: Crispin
Email: send email
Telefono: 496221000000
Fax: 496221000000

DE (HEIDELBERG) participant 545˙487.25
7    KRAEFTENS BEKAEMPELSE

 Organization address address: Strandboulevarden 49
city: KOEBENHAVN
postcode: 2100

contact info
Titolo: Mr.
Nome: Claus Skytte
Cognome: Rasmussen
Email: send email
Telefono: 4535257633
Fax: 4535257731

DK (KOEBENHAVN) participant 519˙662.80
8    FOUNDATION FOR GENOMICS & POPULATION HEALTH

 Organization address address: WORTS CAUSEWAY 2
city: CAMBRIDGE
postcode: CB1 8RN

contact info
Titolo: Ms.
Nome: Carol
Cognome: Lyon
Email: send email
Telefono: +44 1223 741934
Fax: +44 1223 740892

UK (CAMBRIDGE) participant 490˙132.00
9    THE UNIVERSITY OF WARWICK

 Organization address address: Kirby Corner Road - University House -
city: COVENTRY
postcode: CV4 8UW

contact info
Titolo: Dr.
Nome: Peter
Cognome: Hedges
Email: send email
Telefono: +44 24 76523716
Fax: +44 24 76574458

UK (COVENTRY) participant 319˙872.00
10    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Ms.
Nome: Susanne
Cognome: André
Email: send email
Telefono: +46 46 177501
Fax: +46 46 147327

SE (LUND) participant 201˙534.00
11    Nome Ente NON disponibile

 Organization address address: STENBACKINKATU 9
city: HELSINKI
postcode: 29

contact info
Titolo: Ms.
Nome: Mari
Cognome: Frostell
Email: send email
Telefono: +358 400748767
Fax: +358 9 47175404

FI (HELSINKI) participant 201˙471.60
12    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 78132849

UK (LONDON) participant 170˙906.40
13    CENTRE ANTICANCEREUX LEON BERARD

 Organization address address: RUE LAENNEC 28
city: LYON
postcode: 69373

contact info
Titolo: Dr.
Nome: Marina
Cognome: Rousseau-Tsangiris
Email: send email
Telefono: +33 4 78782618
Fax: +33 4 78782955

FR (LYON) participant 136˙884.00
14    BREAST INTERNATIONAL GROUP - AISBL

 Organization address address: BOULEVARD DE WATERLOO 121
city: BRUXELLES
postcode: 1000

contact info
Titolo: Ms.
Nome: Livia
Cognome: Meirsman
Email: send email
Telefono: +32 2 5413526
Fax: +32 2 5413199

BE (BRUXELLES) participant 42˙882.30
15    ANTI CANCER COUNCIL OF VICTORIA

 Organization address address: RATHDOWNE STREET 1
city: CARLTON VICTORIA
postcode: 3053

contact info
Titolo: Ms.
Nome: Priscilla
Cognome: Hinds
Email: send email
Telefono: +61 3 96355086
Fax: +61 3 96355250

AU (CARLTON VICTORIA) participant 0.00
16    QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

 Organization address address: "Herston Road, 300"
city: HERSTON
postcode: QLD 4006

contact info
Titolo: Ms.
Nome: Bronwyn
Cognome: Dunphy
Email: send email
Telefono: +61 7 33620189
Fax: +61 7 33620111

AU (HERSTON) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

tests    first    environmental    lifestyle    underlying    models    prostate    individuals    carcinogenesis    quantifying    biological    loci    intervention    cancer    breast    data    chip    environment    individual    prediction    risk    cogs    genetic    gene    interactions    nature    tumour    strategies    genotyping    snps    therapeutic    certain    cancers    made    variation    variables    disease    world    ovarian   

 Obiettivo del progetto (Objective)

'The overarching goal of COGS is to identify individuals with an increased risk of breast, ovary and prostate cancer. Furthermore, we will evaluate the effect of inherited genetic variation on tumour characteristics and clinical outcome. We will do this through quantifying the role of genetic and environmental/lifestyle risk in the largest data set ever generated. In all, we will include over 200,000 individuals in the COGS project. We will use detailed knowledge of the architecture of genetic susceptibility and interactions with environmental/lifestyle factors which will result in much more accurate individual risk prediction and improved intervention strategies. We are taking advantage of a unique possibility by incorporating seven existing consortia into one large project – COGS. Members of these consortia have collaborated successfully over the past years and results have been presented in world leading scientific journals such as Nature, Nature Genetics and Journal of the National Cancer Institute. These papers reflect that collaboration has been ongoing and that is has so far been very successful. We will also build on an existing European Commission project, TRANSBIG, thus adding value to already spent money. Results generated through COGS will lead to an improved understanding of the biological processes that underlie carcinogenesis, that in turn could guide new therapeutic strategies. Results will also lead to the development of new tests for risk prediction for breast, ovarian and prostate cancer.'

Introduzione (Teaser)

A better understanding of what factors contribute to the risk of certain types of cancer can help in developing both predictive tools and intervention strategies.

Descrizione progetto (Article)

The 'Collaborative oncological gene-environment study' (COGS) project is working to more precisely define the individual risk of disease by taking into account all possible influencing factors. Researchers have five major objectives: to identify genetic variation underlying increased risk for breast, ovarian and prostate cancer; to assess interaction between genetic loci and known or suspected environmental/lifestyle risk factors; to assess whether the link between genetic factors, environmental/lifestyle risk factors and cancer risk is stronger for certain tumour subtypes; to develop comprehensive risk models for these cancers; and to investigate the efficacy and cost-effectiveness of using these risk models in prevention strategies.

Statistical analyses are being used to identify genetic loci through a multi-step procedure, with resulting genotyping results forming the basis for subsequent project activities. Initial work in this EU-funded project has focused on identifying the 200 000 single nucleotide polymorphisms (SNPs) that will be put on the Illumina iSelect chip, to be generated by one of the consortium partners. SNPs, the most common type of genetic variation found in the same biological species, offer information on how genetic make-up is linked to disease development and therapeutic responses.

Datasets have been made up from existing genetic association studies (GWASs) in breast, prostate and ovarian cancer. These will be used to derive estimated genotypes for all subjects.

During the first year of the project, efforts went into quantifying and organising the DNA received from partners all over the world. Actual genotyping has been scheduled to begin when the chip is delivered.

Negotiations have been conducted for the purchase of an iCOGS chip for SNP selection and genotyping. The first cancer chip of its kind, this achievement allows for genotyping across all consortia and provides a means of eliminating candidate SNPs at each locus.

Thanks to advances in methods of data generation, 55 loci (18 loci for breast cancer, 27 for prostate, 6 for ovarian, 4 implicated in various other cancers) have already been examined. Data mining of data released by the 1000 Genomes Project and the Hapmap project have made it possible to compare numbers of the common variants identified.

In work investigating gene-environment interactions placing individuals at risk for cancer, study questionnaires have been uploaded onto the websites of project partners. These links are also provided on the COGS website. Variables for all the risk factors have been coded, with more detailed variables having been defined for more in-depth analysis in subsets to be carried out at a later stage.

As work continues, consortium partners continue to lay the foundations for planned studies in order to fulfil project objectives. COGS researchers expect that as new discoveries are made and environmental/lifestyle factors are identified, the project will succeed in offering explanations for individual variations in disease risk. The results of this project will also lead to enhanced knowledge of the biological processes underlying carcinogenesis. This is important for guiding new therapeutic strategies, as well as for developing tests for risk prediction.

Altri progetti dello stesso programma (FP7-HEALTH)

EUCLYD (2008)

A European Consortium for Lysosomal Disorders

Read More  

SM-BIO-POWER (2008)

Empowering Biomedical and Bioengineering SMEs to promote participation in FP7 projects

Read More  

KINDRED (2013)

Kinetoplastid Drug Development: strengthening the preclinical pipeline

Read More